Neurological disorders are a major global challenge, which counts for a substantial slice of disease burden around the globe. In these, the challenging landscape of central nervous system (CNS) diseases, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and neuro-AIDS, demands innovative and novel therapeutic approaches. Curcumin, a versatile natural compound with antioxidant and anti-inflammatory properties, shows great potential as a CNS adjuvant therapy. However, its limited bioavailability and suboptimal permeability to the blood–brain barrier (BBB) hamper the therapeutic efficacy of curcumin. This review explores how nanocarrier facilitates curcumin delivery, which has shown therapeutic efficacy for various non-CNS diseases, for example, cancers, and can also revolutionize the treatment outcomes in patients with CNS diseases. Toward this, intranasal administration of curcumin as a non-invasive CNS drug delivery route can also aid its therapeutic outcomes as an adjuvant therapy for CNS diseases. Intranasal delivery of nanocarriers with curcumin improves the bioavailability of curcumin and its BBB permeability, which is instrumental in promoting its therapeutic potential. Furthermore, curcumin’s inhibitory effect on efflux transporters will help to enhance the BBB and cellular permeability of various CNS drugs. The therapeutic potential of curcumin as an adjuvant has the potential to yield synergistic effects with CNS drugs and will help to reduce CNS drug doses and improve their safety profile. Taken together, this approach holds a promise for reshaping CNS disease management by maximizing curcumin’s and other drugs’ therapeutic benefits.
KothaRRLuthriaDL.Curcumin: biological, pharmaceutical, nutraceutical, and analytical aspects. Molecules2019;24:2930
2.
MirzaeiHShakeriARashidiBJaliliABanikazemiZSahebkarA.Phytosomal curcumin: a review of pharmacokinetic, experimental and clinical studies. Biomed Pharmacother2017;85:102–12
3.
PriyadarsiniKI.The chemistry of curcumin: from extraction to therapeutic agent. Molecules2014;19:20091–112
4.
AnandPKunnumakkaraABNewmanRAAggarwalBB.Bioavailability of curcumin: problems and promises. Mol Pharm2007;4:807–18
5.
BuhrmannCMobasheriABuschFAldingerCStahlmannRMontaseriAShakibaeiM.Curcumin modulates nuclear factor kappaB (NF-kappaB)-mediated inflammation in human tenocytes in vitro: role of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem2011;286:28556–66
6.
PatelSSAcharyaARayRSAgrawalRRaghuwanshiRJainP.Cellular and molecular mechanisms of curcumin in prevention and treatment of disease. Crit Rev Food Sci Nutr2020;60:887–939
7.
LarasatiYAYoneda-KatoNNakamaeIYokoyamaTMeiyantoEKatoJY.Curcumin targets multiple enzymes involved in the ROS metabolic pathway to suppress tumor cell growth. Sci Rep2018;8:2039
8.
LiczbińskiPMichałowiczJBukowskaB.Molecular mechanism of curcumin action in signaling pathways: review of the latest research. Phytother Res2020;34:1992–2005
9.
WangLWangCTaoZZhaoLZhuZWuWHeYChenHZhengBHuangXYuYYangLLiangGCuiRChenT.Curcumin derivative WZ35 inhibits tumor cell growth via ROS-YAP-JNK signaling pathway in breast cancer. J Exp Clin Cancer Res2019;38:460
10.
GaoLShaoTZhengWDingJ.Curcumin suppresses tumor growth of gemcitabine-resistant non-small cell lung cancer by regulating lncRNA-MEG3 and PTEN signaling. Clin Transl Oncol2021;23:1386–93
AmalrajAVarmaKJacobJDivyaCKunnumakkaraABStohsSJGopiS.A novel highly bioavailable curcumin formulation improves symptoms and diagnostic indicators in rheumatoid arthritis patients: a randomized, double-blind, placebo-controlled, two-dose, three-arm, and parallel-group study. J Med Food2017;20:1022–30
13.
MakuchSWiecekKWozniakM.The immunomodulatory and anti-inflammatory effect of curcumin on immune cell populations, cytokines, and in vivo models of rheumatoid arthritis. Pharmaceuticals2021;14:309
14.
RyanJJHanesDABradleyRDContractorN.Effect of a nutrition support formula in adults with inflammatory bowel disease: a pilot study. Glob Adv Health Med2019;8:2164956119867251
15.
GoulartRABarbalhoSMLimaVMSouzaGAMatiasJNAraújoACRubiraCJBuchaimRLBuchaimDVCarvalhoACAGuiguerÉL.Effects of the use of curcumin on ulcerative colitis and Crohn’s disease: a systematic review. J Med Food2021;24:675–85
16.
ThotaRNAcharyaSHGargML.Curcumin and/or omega-3 polyunsaturated fatty acids supplementation reduces insulin resistance and blood lipids in individuals with high risk of type 2 diabetes: a randomised controlled trial. Lipids Health Dis2019;18:31
17.
AltobelliEAngelettiPMMarzilianoCMastrodomenicoMGiulianiARPetrocelliR.Potential therapeutic effects of curcumin on glycemic and lipid profile in uncomplicated type 2 diabetes-a meta-analysis of randomized controlled trial. Nutrients2021;13:404
18.
ChenGLiuSPanRLiGTangHJiangMXingYJinFLinLDongJ.Curcumin attenuates gp120-induced microglial inflammation by inhibiting autophagy via the PI3K pathway. Cell Mol Neurobiol2018;38:1465–77
19.
GuoLXingYPanRJiangMGongZLinLWangJXiongGDongJ.Curcumin protects microglia and primary rat cortical neurons against HIV-1 gp120-mediated inflammation and apoptosis. PLoS ONE2013;8:e70565
AliABanerjeaAC.Curcumin inhibits HIV-1 by promoting Tat protein degradation. Sci Rep2016;6:27539
22.
AhmadabadySBeheshtiFShahidpourFKhordadEHosseiniM.A protective effect of curcumin on cardiovascular oxidative stress indicators in systemic inflammation induced by lipopolysaccharide in rats. Biochem Biophys Rep2021;25:100908
23.
SangouniAATaghdirMMirahmadiJSepandiMParastoueiK.Effects of curcumin and/or coenzyme Q10 supplementation on metabolic control in subjects with metabolic syndrome: a randomized clinical trial. Nutr J2022;21:62
24.
du PreezRPahlJAroraMRavi KumarMNVBrownLPanchalSK.Low-dose curcumin nanoparticles normalise blood pressure in male wistar rats with diet-induced metabolic syndrome. Nutrients2019;11:1542
25.
ZhangJZhengYLuoYDuYZhangXFuJ.Curcumin inhibits LPS-induced neuroinflammation by promoting microglial M2 polarization via TREM2/ TLR4/ NF-kappaB pathways in BV2 cells. Mol Immunol2019;116:29–37
26.
SamarghandianSAzimi-NezhadMFarkhondehTSaminiF.Anti-oxidative effects of curcumin on immobilization-induced oxidative stress in rat brain, liver and kidney. Biomed Pharmacother2017;87:223–9
27.
HeHJXiongXZhouSZhangXRZhaoXChenLXieCL.Neuroprotective effects of curcumin via autophagy induction in 6-hydroxydopamine Parkinson’s models. Neurochem Int2022;155:105297
28.
KhurshidBRehmanAUMuhammadSWadoodAAnwarJ.Toward the noninvasive diagnosis of Alzheimer’s disease: molecular basis for the specificity of curcumin for fibrillar amyloid-beta. ACS Omega2022;7:22032–8
29.
GreenfieldSAColeGMCoenCWFrautschySSinghRPMekkittikulMGarcia-RatésSMorrillPHollingsOPassmoreMHasanSCartyNBisonSPiccoliLCarlettiRTacconiSChalidouAPederciniMKroecherTAstnerHGerrardPA.A novel process driving Alzheimer’s disease validated in a mouse model: therapeutic potential. Alzheimers Dement2022;8:e12274
30.
DengYLuXWangLLiTDingYCaoHZhangYGuoXYuG.Curcumin inhibits the AKT/NF-kappaB signaling via CpG demethylation of the promoter and restoration of NEP in the N2a cell line. AAPS J2014;16:649–57
31.
SharmaNNehruB.Curcumin affords neuroprotection and inhibits alpha-synuclein aggregation in lipopolysaccharide-induced Parkinson’s disease model. Inflammopharmacology2018;26:349–60
32.
LinXBaiDWeiZZhangYHuangYDengHHuangX.Curcumin attenuates oxidative stress in RAW264.7 cells by increasing the activity of antioxidant enzymes and activating the Nrf2-Keap1 pathway. PLoS ONE2019;14:e0216711
33.
LiGDuanLYangFYangLDengYYuYXuYZhangY.Curcumin suppress inflammatory response in traumatic brain injury via p38/MAPK signaling pathway. Phytother Res2022;36:1326–37
34.
ELBini-DhouibINeiliNEMarzoukiSSahraouiGBen AchourWZouaghiSBenAhmedMDoghriRSrairi-AbidN.Dual mechanism of action of curcumin in experimental models of multiple sclerosis. Int J Mol Sci2022;23:8658
35.
ZhangWYGuoYJHanWXYangMQWenLPWangKYJiangP.Curcumin relieves depressive-like behaviors via inhibition of the NLRP3 inflammasome and kynurenine pathway in rats suffering from chronic unpredictable mild stress. Int Immunopharmacol2019;67:138–44
36.
ZhaoSYangJHanXGongYRaoSWuBYiZZouLJiaTLiLYuanHShiLZhangCGaoYLiGLiuSXuHLiuHLiangS.Effects of nanoparticle-encapsulated curcumin on HIV-gp120-associated neuropathic pain induced by the P2X(3) receptor in dorsal root ganglia. Brain Res Bull2017;135:53–61
37.
XiaCCaiYLiSYangJXiaoG.Curcumin increases HSP70 expression in primary rat cortical neuronal apoptosis induced by gp120 V3 loop peptide. Neurochem Res2015;40:1996–2005
38.
MoghaddamAHMaboudiKBavagharBSangdehiSRMZareM.Neuroprotective effects of curcumin-loaded nanophytosome on ketamine-induced schizophrenia-like behaviors and oxidative damage in male mice. Neurosci Lett2021;765:136249
39.
FeiginVLVosTNicholsEOwolabiMOCarrollWMDichgansMDeuschlGParmarPBraininMMurrayC.The global burden of neurological disorders: translating evidence into policy. Lancet Neurol2020;19:255–65
40.
ChitiFDobsonCM.Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem2006;75:333–66
41.
MonacoAFraldiA.Protein aggregation and dysfunction of autophagy-lysosomal pathway: a vicious cycle in lysosomal storage diseases. Front Mol Neurosci2020;13:37
42.
CummingsJLeeGZhongKFonsecaJTaghvaK.Alzheimer’s disease drug development pipeline: 2021. Alzheimers Dement2021;7:e12179
43.
AtharTAl BalushiKKhanSA.Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease. Mol Biol Rep2021;48:5629–45
44.
SweeneyMDZhaoZMontagneANelsonARZlokovicBV.Blood-brain barrier: from physiology to disease and back. Physiol Rev2019;99:21–78
45.
DongYLiJLiPYuJ.Ultrasound microbubbles enhance the activity of vancomycin against Staphylococcus epidermidis biofilms in vivo. J Ultrasound Med2018;37:1379–87
46.
TerstappenGCMeyerAHBellRDZhangW.Strategies for delivering therapeutics across the blood-brain barrier. Nat Rev Drug Discov2021;20:362–83
47.
DingSKhanAICaiXSongYLyuZDuDDuttaPLinY.Overcoming blood-brain barrier transport: advances in nanoparticle-based drug delivery strategies. Mater Today2020;37:112–25
48.
PanditRChenLGötzJ.The blood-brain barrier: physiology and strategies for drug delivery. Adv Drug Deliv Rev2020;165–166:1–14
49.
PinheiroRGRCoutinhoAJPinheiroMNevesAR. Nanoparticles for targeted brain drug delivery: what do we know?Int J Mol Sci2021;22:11654
50.
AlotaibiBSBuabeidMIbrahimNAKharabaZJIjazMNoreenSMurtazaG.Potential of nanocarrier-based drug delivery systems for brain targeting: a current review of literature. Int J Nanomedicine2021;16:7517–33
51.
Dell’AcquaGRichardsAThorntonMJ.The potential role of nutraceuticals as an adjuvant in breast cancer patients to prevent hair loss induced by endocrine therapy. Nutrients2020;12:3537
52.
ReedDRainaKAgarwalR.Nutraceuticals in prostate cancer therapeutic strategies and their neo-adjuvant use in diverse populations. NPJ Precis Oncol2018;2:15
53.
Lopes-RodriguesVSousaEVasconcelosMH.Curcumin as a modulator of P-glycoprotein in cancer: challenges and perspectives. Pharmaceuticals2016;9:71
54.
JamwalR.Bioavailable curcumin formulations: a review of pharmacokinetic studies in healthy volunteers. J Integr Med2018;16:367–74
55.
BansalSSGoelMAqilFVadhanamMVGuptaRC.Advanced drug delivery systems of curcumin for cancer chemoprevention. Cancer Prev Res2011;4:1158–71
56.
KarthikeyanASenthilNMinT.Nanocurcumin: a promising candidate for therapeutic applications. Front Pharmacol2020;11:487
57.
ShaikhJAnkolaDDBeniwalVSinghDKumarMN.Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci2009;37:223–30
58.
Sharifi-RadJRayessYERizkAASadakaCZgheibRZamWSestitoSRapposelliSNeffe-SkocińskaKZielińskaDSalehiBSetzerWNDosokyNSTaheriYEl BeyrouthyMMartorellMOstranderEASuleriaHARChoWCMaroyiAMartinsN.Turmeric and its major compound curcumin on health: bioactive effects and safety profiles for food, pharmaceutical, biotechnological and medicinal applications. Front Pharmacol2020;11:01021
59.
KhanMNHaggagYALaneMEMcCarronPATambuwalaMM.Polymeric nano-encapsulation of curcumin enhances its anti-cancer activity in breast (MDA-MB231) and lung (A549) cancer cells through reduction in expression of HIF-1alpha and nuclear p65 (Rel A). Curr Drug Deliv2018;15:286–95
60.
KunduMSadhukhanPGhoshNChatterjeeSMannaPDasJSilPC.pH-responsive and targeted delivery of curcumin via phenylboronic acid-functionalized ZnO nanoparticles for breast cancer therapy. J Adv Res2019;18:161–72
61.
GuptaABriffaSMSwinglerSGibsonHKannappanVAdamusGKowalczukMMartinCRadeckaI.Synthesis of silver nanoparticles using curcumin-cyclodextrins loaded into bacterial cellulose-based hydrogels for wound dressing applications. Biomacromolecules2020;21:1802–11
62.
ChaubeyPPatelRRMishraB.Development and optimization of curcumin-loaded mannosylated chitosan nanoparticles using response surface methodology in the treatment of visceral leishmaniasis. Expert Opin Drug Deliv2014;11:1163–81
63.
NiranjanRKaushikMPrakashJVenkataprasannaKSPremaDChristyAPannerselvamBDevanand VenkatasubbuG.Chitosan based wound dressing patch loaded with curcumin tagged ZnO nanoparticles for potential wound healing application. Inorg Chem Commun2023;154:110885
64.
ChangCZWuSCLinCLKwanAL.Curcumin, encapsulated in nano-sized PLGA, down-regulates nuclear factor kappaB (p65) and subarachnoid hemorrhage induced early brain injury in a rat model. Brain Res2015;1608:215–24
65.
ZhangZYJiangMFangJYangMFZhangSYinYXLiDWMaoLLFuXYHouYJFuXTFanCDSunBL.Enhanced therapeutic potential of nano-curcumin against subarachnoid hemorrhage-induced blood-brain barrier disruption through inhibition of inflammatory response and oxidative stress. Mol Neurobiol2017;54:1–14
66.
GaoCWangYSunJHanYGongWLiYFengYWangHYangMLiZYangYGaoC.Neuronal mitochondria-targeted delivery of curcumin by biomimetic engineered nanosystems in Alzheimer’s disease mice. Acta Biomater2020;108:285–99
67.
ParikhAKathawalaKLiJChenCShanZCaoXZhouXFGargS.Curcumin-loaded self-nanomicellizing solid dispersion system: part II: in vivo safety and efficacy assessment against behavior deficit in Alzheimer disease. Drug Deliv Transl Res2018;8:1406–20
68.
ZhangNYanFLiangXWuMShenYChenMXuYZouGJiangPTangCZhengHDaiZ.Localized delivery of curcumin into brain with polysorbate 80-modified cerasomes by ultrasound-targeted microbubble destruction for improved Parkinson’s disease therapy. Theranostics2018;8:2264–77
69.
OrunogluMKaffashiAPehlivanSBSahinSSoylemezogluFOguzKKMutM.Effects of curcumin-loaded PLGA nanoparticles on the RG2 rat glioma model. Mater Sci Eng C Mater Biol Appl2017;78:32–8
70.
HuangNLuSLiuXGZhuJWangYJLiuRT.PLGA nanoparticles modified with a BBB-penetrating peptide co-delivering Abeta generation inhibitor and curcumin attenuate memory deficits and neuropathology in Alzheimer’s disease mice. Oncotarget2017;8:81001–13
71.
ValizadehHAbdolmohammadi-VahidSDanshinaSZiya GencerMAmmariASadeghiARoshangarLAslaniSEsmaeilzadehAGhaebiMValizadehSAhmadiM.Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients. Int Immunopharmacol2020;89:107088
72.
BateniZRahimiHRHedayatiMAfsharianSGoudarziRSohrabG.The effects of nano-curcumin supplementation on glycemic control, blood pressure, lipid profile, and insulin resistance in patients with the metabolic syndrome: a randomized, double-blind clinical trial. Phytother Res2021;35:3945–53
73.
NiranjanRKaushikMPrakashJVenkataprasannaKSArpanaCBalashanmugamPVenkatasubbuGD.Enhanced wound healing by PVA/Chitosan/curcumin patches: in vitro and in vivo study. Colloids Surf B Biointerfaces2019;182:110339
74.
BajpaiSKAhujaSChandNBajpaiM.Nano cellulose dispersed chitosan film with Ag NPs/Curcumin: an in vivo study on albino rats for wound dressing. Int J Biol Macromol2017;104:1012–9
75.
AsadiSGholamiMSSiassiFQorbaniMSotoudehG.Beneficial effects of nano-curcumin supplement on depression and anxiety in diabetic patients with peripheral neuropathy: a randomized, double-blind, placebo-controlled clinical trial. Phytother Res2020;34:896–903
76.
AbdolahiMKarimiESarrafPTafakhoriASiriGSalehiniaFSedighiyanMAsanjaraniBBadeliMAbdollahiHYoosefiNYousefiARadASDjalaliM.The omega-3 and nano-curcumin effects on vascular cell adhesion molecule (VCAM) in episodic migraine patients: a randomized clinical trial. BMC Res Notes2021;14:283
77.
Jazayeri-TehraniSARezayatSMMansouriSQorbaniMAlavianSMDaneshi-MaskooniMHosseinzadeh-AttarMJ.Nano-curcumin improves glucose indices, lipids, inflammation, and nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial. Nutr Metab2019;16:8
78.
LuWTangHLiSBaiLChenY.Extracellular vesicles as potential biomarkers and treatment options for liver failure: a systematic review up to March 2022. Front Immunol2023;14:1116518
79.
HommaKBazhanovNHashimotoKShimizuMHeathmanTHaoQNawgiriRMuthukumaranaVLeeJWProughDSEnkhbaatarP.Mesenchymal stem cell-derived exosomes for treatment of sepsis. Front Immunol2023;14:1136964
80.
HeXWangYLiuZWengYChenSPanQLiYWangHLinSYuH.Osteoporosis treatment using stem cell-derived exosomes: a systematic review and meta-analysis of preclinical studies. Stem Cell Res Ther2023;14:72
81.
HeXZhangCAmirsaadatSJalilATKadhimMMAbasiMPilehvarY.Curcumin-loaded mesenchymal stem cell-derived exosomes efficiently attenuate proliferation and inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes. Appl Biochem Biotechnol2023;195:51–67
82.
KalaniAKamatPKChaturvediPTyagiSCTyagiN.Curcumin-primed exosomes mitigate endothelial cell dysfunction during hyperhomocysteinemia. Life Sci2014;107:1–7
83.
ZhouLKodidelaSGodseSThomas-GoochSKumarARajiBZhiKKochatHKumarS.Targeted drug delivery to the central nervous system using extracellular vesicles. Pharmaceuticals2022;15:358
84.
UpadhyaRShettyAK.Extracellular vesicles for the diagnosis and treatment of Parkinson’s disease. Aging Dis2021;12:1438–50
85.
LiuLLiYPengHLiuRJiWShiZShenJMaGZhangX.Targeted exosome coating gene-chem nanocomplex as “nanoscavenger” for clearing alpha-synuclein and immune activation of Parkinson’s disease. Sci Adv2020;6:eaba3967
86.
MobahatMSadroddinyENooshabadiVTEbrahimi-BaroughSGoodarziAMalekshahiZVAiJ.Curcumin-loaded human endometrial stem cells derived exosomes as an effective carrier to suppress alpha-synuclein aggregates in 6OHDA-induced Parkinson’s disease mouse model. Cell Tissue Bank2023;24:75–91
87.
WangHSuiHZhengYJiangYShiYLiangJZhaoL.Curcumin-primed exosomes potently ameliorate cognitive function in AD mice by inhibiting hyperphosphorylation of the Tau protein through the AKT/GSK-3beta pathway. Nanoscale2019;11:7481–96
88.
FernandesMLopesIMagalhaesLSarriaMPMachadoRSousaJCBotelhoCTeixeiraJGomesAC.Novel concept of exosome-like liposomes for the treatment of Alzheimer’s disease. J Control Release2021;336:130–43
89.
HeRJiangYShiYLiangJZhaoL.Curcumin-laden exosomes target ischemic brain tissue and alleviate cerebral ischemia-reperfusion injury by inhibiting ROS-mediated mitochondrial apoptosis. Mater Sci Eng C Mater Biol Appl2020;117:111314
90.
TianTZhangHXHeCPFanSZhuYLQiCHuangNPXiaoZDLuZHTannousBAGaoJ.Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy. Biomaterials2018;150:137–49
91.
CroweTPHsuWH.Evaluation of recent intranasal drug delivery systems to the central nervous system. Pharmaceutics2022;14:629
92.
KumarAZhouLGodseSSinhaNMaDParmarKKumarS.Intranasal delivery of darunavir improves brain drug concentrations in mice for effective HIV treatment. Biochem Biophys Rep2023;33:101408
93.
KozlovskayaLAbou-KaoudMStepenskyD.Quantitative analysis of drug delivery to the brain via nasal route. J Control Release2014;189:133–40
94.
KumarNNLochheadJJPizzoMENehraGBoroumandSGreeneGThorneRG.Delivery of immunoglobulin G antibodies to the rat nervous system following intranasal administration: distribution, dose-response, and mechanisms of delivery. J Control Release2018;286:467–84
95.
CraftSRamanRChowTWRafiiMSSunCKRissmanRADonohueMCBrewerJBJenkinsCHarlessKGessertDAisenPS.Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia: a randomized clinical trial. JAMA Neurol2020;77:1099–109
96.
DetynieckiKVan EssPJSequeiraDJWhelessJWMengTCPullmanWE.Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters-a randomized, double-blind, placebo-controlled trial. Epilepsia2019;60:1797–808
97.
ShindeRLDevarajanPV.Docosahexaenoic acid-mediated, targeted and sustained brain delivery of curcumin microemulsion. Drug Deliv2017;24:152–61
98.
ChenXZhiFJiaXZhangXAmbardekarRMengZParadkarARHuYYangY.Enhanced brain targeting of curcumin by intranasal administration of a thermosensitive poloxamer hydrogel. J Pharm Pharmacol2013;65:807–16
99.
DendeCMeenaJNagarajanPNagarajVAPandaAKPadmanabanG.Nanocurcumin is superior to native curcumin in preventing degenerative changes in experimental cerebral malaria. Sci Rep2017;7:10062
100.
BusariZADaudaKAMorenikejiOAAfolayanFOyeyemiOTMeenaJSahuDPandaAK.Antiplasmodial activity and toxicological assessment of curcumin PLGA-encapsulated nanoparticles. Front Pharmacol2017;8:622
101.
SunLLiuZWangLCunDTongHHYYanRChenXWangRZhengY.Enhanced topical penetration, system exposure and anti-psoriasis activity of two particle-sized, curcumin-loaded PLGA nanoparticles in hydrogel. J Control Release2017;254:44–54
102.
AnwarSKElmonaemSNAMoussaEAboulelaAGEssawyMM.Curcumin nanoparticles: the topical antimycotic suspension treating oral candidiasis. Odontology2023;111:350–9
103.
WangWZhuRXieQLiAXiaoYLiKLiuHCuiDChenYWangS.Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles. Int J Nanomedicine2012;7:3667–77
104.
SuXJingXJiangWLiMLiuKTengMMaYWangDMengLZhangYJiW.Polyphosphazene nanodrugs for targeting delivery and inflammation responsive release of curcumin to treat acute lung injury by effectively inhibiting cytokine storms. Colloids Surf B Biointerfaces2023;229:113446
105.
GhasemiSZBeigoliSBehrouzSGholamnezhadZMohammadian RoshanNBoskabadyMH.Evaluation of nano-curcumin against inhaled paraquat-induced lung injury in rats. Pharmacol Rep2023;75:671–81
106.
KimMKimS-BKimJKimK-SKimD-E.Co-delivery of curcumin and PTTG1 siRNA by galactose receptor-targeted liposomes for enhanced anti-tumor effects in hepatocellular carcinoma. J Drug Deliv Sci Technol2023;86:104692
107.
SongJWLiuYSGuoYRZhongWXGuoYPGuoL.Nano-liposomes double loaded with curcumin and tetrandrine: preparation, characterization, hepatotoxicity and anti-tumor effects. Int J Mol Sci2022;23:6858
108.
ZamanMSChauhanNYallapuMMGaraRKMaherDMKumariSSikanderMKhanSZafarNJaggiMChauhanSC.Curcumin nanoformulation for cervical cancer treatment. Sci Rep2016;6:20051
109.
MatloubiZHassanZ.HSA-curcumin nanoparticles: a promising substitution for curcumin as a cancer chemoprevention and therapy. Daru2020;28:209–19
110.
AliIAhmedSBMElhajBMAliHSAlsubaieAAlmalkiASA. Enhanced anticancer activities of curcumin-loaded green gum acacia-based silver nanoparticles against melanoma and breast cancer cells. Applied Nanoscience2021;11:2679–87
111.
SabourianPJiJLotockiVMoquinAHannaRFrounchiMMaysingerDKakkarA.Facile design of autogenous stimuli-responsive chitosan/hyaluronic acid nanoparticles for efficient small molecules to protein delivery. J Mater Chem B2020;8:7275–87
112.
ZhangZZhangX.Curcumin loading on alginate nano-micelle for anti-infection and colonic wound healing. J Biomed Nanotechnol2021;17:1160–9
113.
KangBKYuZChenWJiangTShimYHGaoJZhouGCaoD.Using gelatin/curcumin nano-fiber membranes as scaffolds in a subcutaneous model for tissue engineered cartilages. Cell Tissue Bank2021;22:443–51
114.
DaiXLiuJZhengHWichmannJHopfnerUSudhopSPreinCShenYMachensH-GSchillingAF.Nano-formulated curcumin accelerates acute wound healing through Dkk-1-mediated fibroblast mobilization and MCP-1-mediated anti-inflammation. NPG Asia Mater2017;9:e368–168
115.
MarulasiddeshwaraRJyothiMSSoontarapaKKeriRSVelmuruganR.Nonwoven fabric supported, chitosan membrane anchored with curcumin/TiO(2) complex: scaffolds for MRSA infected wound skin reconstruction. Int J Biol Macromol2020;144:85–93
116.
MirzahosseinipourMKhorsandiKHosseinzadehRGhazaeianMShahidiFK.Antimicrobial photodynamic and wound healing activity of curcumin encapsulated in silica nanoparticles. Photodiagnosis Photodyn Ther2020;29:101639
117.
LeeHJJeongMNaYGKimSJLeeHKChoCW.An EGF- and curcumin-co-encapsulated nanostructured lipid carrier accelerates chronic-wound healing in diabetic rats. Molecules2020;25:4610
118.
KrauszAEAdlerBLCabralVNavatiMDoernerJCharafeddineRAChandraDLiangHGuntherLClendanielAHarperSFriedmanJMNosanchukJDFriedmanAJ.Curcumin-encapsulated nanoparticles as innovative antimicrobial and wound healing agent. Nanomedicine2015;11:195–206
119.
NguyenTPWilczewskiSLewandowskiJMajkowska-PilipAŻelechowska-MatysiakKNiecieckaDStudzińskiWOlusegunSJSyczewskiMGiersigMDinhTMTKrysińskiPOsialM.5-fluorouracil and curcuminoids extract from Curcuma longa L. loaded into nanohydroxyapatite as a drug delivery carrier for SKOV-3 and Hepg2 cancer cells treatment. Ceramics International2023;49:25775–87
120.
SadraeiMRTavalaeeMForouzanfarMNasr-EsfahaniMH.Effect of curcumin, and nano-curcumin on sperm function in varicocele rat model. Andrologia2022;54:e14282
121.
NasrMAhmed-FaridOAHAhmedRF.Curcumin-resveratrol nano-formulation counteracting hyperammonemia in rats. Metab Brain Dis2023;38:1365–77
122.
GanugulaRAroraMJaisamutPWiwattanapatapeeRJørgensenHGVenkatpurwarVPZhouBRodrigues HoffmannABasuRGuoSMajetiNVRK. Nano-curcumin safely prevents streptozotocin-induced inflammation and apoptosis in pancreatic beta cells for effective management of type 1 diabetes mellitus. Br J Pharmacol2017;174:2074–84
123.
El-FarYMZakariaMMGabrMMEl GayarAMEissaLAEl-SherbinyIM.Nanoformulated natural therapeutics for management of streptozotocin-induced diabetes: potential use of curcumin nanoformulation. Nanomedicine2017;12:1689–711
124.
YangRZhengYWangQZhaoL.Curcumin-loaded chitosan-bovine serum albumin nanoparticles potentially enhanced Abeta 42 phagocytosis and modulated macrophage polarization in Alzheimer’s disease. Nanoscale Res Lett2018;13:330
125.
RayBBishtSMaitraAMaitraALahiriDK.Neuroprotective and neurorescue effects of a novel polymeric nanoparticle formulation of curcumin (NanoCurc) in the neuronal cell culture and animal model: implications for Alzheimer’s disease. J Alzheimers Dis2011;23:61–77
126.
GiacomeliRIzotonJCDos SantosRBBoeiraSPJesseCRHaasSE.Neuroprotective effects of curcumin lipid-core nanocapsules in a model Alzheimer’s disease induced by beta-amyloid 1-42 peptide in aged female mice. Brain Res2019;1721:146325
127.
SintovAC.AmyloLipid nanovesicles: a self-assembled lipid-modified starch hybrid system constructed for direct nose-to-brain delivery of curcumin. Int J Pharm2020;588:119725
128.
HuoXZhangYJinXLiYZhangL.A novel synthesis of selenium nanoparticles encapsulated PLGA nanospheres with curcumin molecules for the inhibition of amyloid beta aggregation in Alzheimer’s disease. J Photochem Photobiol B2019;190:98–102
129.
KunduPDasMTripathyKSahooSK.Delivery of dual drug loaded lipid based nanoparticles across the blood-brain barrier impart enhanced neuroprotection in a rotenone induced mouse model of Parkinson’s disease. ACS Chem Neurosci2016;7:1658–70
130.
BollimpelliVSKumarPKumariSKondapiAK.Neuroprotective effect of curcumin-loaded lactoferrin nano particles against rotenone induced neurotoxicity. Neurochem Int2016;95:37–45
131.
HassaniazadMInchehsablaghBRKamaliHTousiAEftekharEJaafariMRFathalipourMNikoofal-SahlabadiSGouklaniHAlizadeHNikpoorAR.The clinical effect of nano micelles containing curcumin as a therapeutic supplement in patients with COVID-19 and the immune responses balance changes following treatment: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21:876
132.
NaeiniFTutunchiHRazmiHMahmoodpoorAVajdiMSefidmooye AzarPNajifipourFTarighat-EsfanjaniAKarimiA.Does nano-curcumin supplementation improve hematological indices in critically ill patients with sepsis? A randomized controlled clinical trial. J Food Biochem2022;46:e14093
133.
AsadiradANashibiRKhodadadiAGhadiriAASadeghiMAminianADehnaviS.Antiinflammatory potential of nano-curcumin as an alternative therapeutic agent for the treatment of mild-to-moderate hospitalized COVID-19 patients in a placebo-controlled clinical trial. Phytother Res2022;36:1023–31
134.
SedighiyanMAbdolahiMJafariEVahabiZSohrabi AtharSHadaviSNarimani ZamanabadiMYekaninejadMSDjalaliM.The effects of nano-curcumin supplementation on adipokines levels in obese and overweight patients with migraine: a double blind clinical trial study. BMC Res Notes2022;15:189
135.
KarimiANaeiniFNiazkarHRTutunchiHMusazadehVMahmoodpoorAAsghariazarVMobasseriMTarighat-EsfanjaniA.Nano-curcumin supplementation in critically ill patients with sepsis: a randomized clinical trial investigating the inflammatory biomarkers, oxidative stress indices, endothelial function, clinical outcomes and nutritional status. Food Funct2022;13:6596–612
136.
TalakeshTTabatabaeeNAtoofFAliasgharzadehASarvizadeMFarhoodBNajafiM.Effect of nano-curcumin on radiotherapy-induced skin reaction in breast cancer patients: a randomized, triple-blind, placebo-controlled trial. Curr Radiopharm2022;15:332–40
137.
KiaSJBasiratMMortezaieTMoosaviMS.Comparison of oral nano-curcumin with oral prednisolone on oral lichen planus: a randomized double-blinded clinical trial. BMC Complement Med Ther2020;20:328
138.
ParohanMSarrafPJavanbakhtMHForoushaniARRanji-BurachalooSDjalaliM.The synergistic effects of nano-curcumin and coenzyme Q10 supplementation in migraine prophylaxis: a randomized, placebo-controlled, double-blind trial. Nutr Neurosci2021;24:317–26
139.
DjalaliMAbdolahiMHosseiniRMiraghajaniMMohammadiHDjalaliM.The effects of nano-curcumin supplementation on Th2/tregulatory axis in migraine patients: a randomized, double-blind, placebo-controlled trial. Int J Neurosci2023;133:169–75
140.
SedighiyanMJafariEAtharSSYekaninejadMSAlvandiEAbdolahiMDjalaliM.The effects of nano-curcumin supplementation on leptin and adiponectin in migraine patients: a double-blind clinical trial study from gene expression to clinical symptoms. Endocr Metab Immune Disord Drug Targets2023;23:711–20
141.
DjalaliMAbdolahiMHosseiniRMiraghajaniMMohammadiHDjalaliM.The effects of nano-curcumin supplementation on Th1/Th17 balance in migraine patients: a randomized controlled clinical trial. Complement Ther Clin Pract2020;41:101256
142.
AsadiSGholamiMSSiassiFQorbaniMKhamoshianKSotoudehG.Nano curcumin supplementation reduced the severity of diabetic sensorimotor polyneuropathy in patients with type 2 diabetes mellitus: a randomized double-blind placebo-controlled clinical trial. Complement Ther Med2019;43:253–60
143.
Vafadar AfsharGRasmiYYaghmaeiPKhadem-AnsariMHMakhdomiiKRasooliJ.The effects of nano-curcumin supplementation on serum level of hs-CRP, adhesion molecules, and lipid profiles in hemodialysis patients, a randomized controlled clinical trial. Iran J Kidney Dis2020;14:52–61
144.
ShafabakhshRAsemiZReinerZSoleimaniAAghadavodEBahmaniF.The effects of nano-curcumin on metabolic status in patients with diabetes on hemodialysis, a randomized, double blind, placebo-controlled trial. Iran J Kidney Dis2020;14:290–9
145.
DastaniMRahimiHRAskariVRJaafariMRJarahiLYadollahiARahimiVB.Three months of combination therapy with nano-curcumin reduces the inflammation and lipoprotein (a) in type 2 diabetic patients with mild to moderate coronary artery disease: evidence of a randomized, double-blinded, placebo-controlled clinical trial. Biofactors2023;49:108–18
146.
HonarvarNMSoveidNAbdolahiMDjalaliMHatamiMKarzarNH.Anti-neuroinflammatory properties of n-3 fatty acids and nano-curcumin on migraine patients from cellular to clinical insight: a randomized, double-blind and placebo-controlled trial. Endocr Metab Immune Disord Drug Targets2021;21:365–73
147.
HelliBGeramiHKavianpourMHeybarHHosseiniSKHaghighianHK.Curcumin nanomicelle improves lipid profile, stress oxidative factors and inflammatory markers in patients undergoing coronary elective angioplasty; a randomized clinical trial. Endocr Metab Immune Disord Drug Targets2021;21:2090–8
148.
AbdolahiMJafariehASarrafPSedighiyanMYousefiATafakhoriAAbdollahiHSalehiniaFDjalaliM.The neuromodulatory effects of omega-3 fatty acids and nano-curcumin on the COX-2/ iNOS network in migraines: a clinical trial study from gene expression to clinical symptoms. Endocr Metab Immune Disord Drug Targets2019;19:874–84
149.
AbdolahiMSarrafPJavanbakhtMHHonarvarNMHatamiMSoveydNTafakhoriASedighiyanMDjalaliMJafariehAMasoudianYDjalaliM.A novel combination of omega-3 fatty acids and nano-curcumin modulates interleukin-6 gene expression and high sensitivity C-reactive protein serum levels in patients with migraine: a randomized clinical trial study. CNS Neurol Disord Drug Targets2018;17:430–8
150.
AbdolahiMTafakhoriAToghaMOkhovatAASiassiFEshraghianMRSedighiyanMDjalaliMMohammadzadeh HonarvarNDjalaliM.The synergistic effects of omega-3 fatty acids and nano-curcumin supplementation on tumor necrosis factor (TNF)-alpha gene expression and serum level in migraine patients. Immunogenetics2017;69:371–8
151.
SoveydNAbdolahiMDjalaliMHatamiMTafakhoriASarrafPHonarvarNM.The combined effects of omega -3 fatty acids and nano-curcumin supplementation on intercellular adhesion molecule-1 (ICAM-1) gene expression and serum levels in migraine patients. CNS Neurol Disord Drug Targets2018;16:1120–6
152.
SasakiHSunagawaYTakahashiKImaizumiAFukudaHHashimotoTWadaHKatanasakaYKakeyaHFujitaMHasegawaKMorimotoT.Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull2011;34:660–5
153.
RamezaniVGhadirianSShabaniMBoroumandMADaneshvarRSaghafiF.Efficacy of curcumin for amelioration of radiotherapy-induced oral mucositis: a preliminary randomized controlled clinical trial. BMC Cancer2023;23:354
154.
BakhshiMMahboubiAJaafariMREbrahimiFTofangchihaMAlizadehA.Comparative efficacy of 1% curcumin nanomicelle gel and 2% curcumin gel for treatment of recurrent aphthous stomatitis: a double-blind randomized clinical trial. J Evid Based Dent Pract2022;22:101708
155.
HassaniazadMEftekharEInchehsablaghBRKamaliHTousiAJaafariMRRafatMFathalipourMNikoofal-SahlabadiSGouklaniHAlizadeHNikpoorAR.A triple-blind, placebo-controlled, randomized clinical trial to evaluate the effect of curcumin-containing nanomicelles on cellular immune responses subtypes and clinical outcome in COVID-19 patients. Phytother Res2021;35:6417–27
156.
HashemzadehKDavoudianNJaafariMRMirfeiziZ.The effect of nanocurcumin in improvement of knee osteoarthritis: a randomized clinical trial. Curr Rheumatol Rev2020;16:158–64
157.
TalebiSDayASSafarianMSayediSJJaafariMRAbbasiZBarghchiHKianifarHR.Adjunctive nano-curcumin therapy improves inflammatory and clinical indices in children with cystic fibrosis: a randomized clinical trial. Food Sci Nutr2023;11:3348–57
158.
CheginiMSadeghiAZaeriFZamaniMHekmatdoostA.Nano-curcumin supplementation in patients with mild and moderate acute pancreatitis: a randomized, placebo-controlled trial. Phytother Res. Epub ahead of print 25 July 2023. DOI: 10.1002/ptr.7958.
159.
KaramiAAZameniHSalehiMMirhashemiSM.The nano-micellar curcumin improves International Prostate Symptoms Score (IPSS) in patients with benign prostatic hyperplasia: a randomized clinical trial. World J Urol2023;41:2465–71
160.
SadeghizadehMAsadollahiEJahangiriBYadollahzadehMMohajeriMAfsharpadMNajafiFRezaieNEskandariMTavakoli-ArdakaniMFeizabadiFMasjediMR.Promising clinical outcomes of nano-curcumin treatment as an adjunct therapy in hospitalized COVID-19 patients: a randomized, double-blinded, placebo-controlled trial. Phytother Res2023;37:3631–44
161.
DebSBhargavaDBansalPKanuruV.Role of nano curcumin on superoxide dismutase levels in leukoplakia. J Oral Maxillofac Pathol2022;26:21–5
162.
OsaliA.Aerobic exercise and nano-curcumin supplementation improve inflammation in elderly females with metabolic syndrome. Diabetol Metab Syndr2020;12:26
